Identifying opportunities for expanding SAMBA use to Faith-based and other organisations supporting HIV monitoring in treatment programmes in Sub-Saharan Africa and Eastern Europe

“DRW开发了SAMBA，这是一种核酸检测系统，可在农村和偏远地区的护理点使用，用于检测艾滋病毒载量，以便对艾滋病毒阳性母亲所生婴儿进行治疗监测和早期艾滋病毒感染诊断，以便进行早期治疗。SAMBA仪器和测试具有ce标志，允许在欧洲和非洲使用。DRW需要开发市场，并正在与几个非洲国家的卫生部和乌克兰的一家医院合作实施SAMBA。在非洲，与政府有关的挑战被证明是一个缓慢而迂回的过程。然而，有一些在当地工作的私人组织需要适当的工具来在偏远、分散的环境中检测艾滋病毒。DRW已经在与无国界医生组织合作，这个项目建议在继续与政府组织合作的同时，确定和量化私人卫生组织的额外机会，例如基于信仰的卫生提供者和非政府组织。据估计，非洲有10万个宗教组织向穷人和弱势群体提供保健服务，可能占全球艾滋病毒/艾滋病工作的20%。在乌干达，非政府组织提供的卫生服务占所有卫生服务的25%，私营非营利组织（包括非政府组织）占医院的41%和较低级卫生设施的22%。这些组织非常积极地向急需但负担不起的人提供卫生保健。DRW建议在目前无法进入的非洲和东欧市场确定并与这些组织合作，并制定向这些市场提供SAMBA的商业战略。收集到的信息将用于制定向这些组织提供测试的适当和可持续的战略。将研究以下信息：a)确定“第二阶段”后续实施的国家、组织和地点；B)确定每年所需的检测次数；C)确定价格的可接受性；D)了解测试场地环境、设施和用户；e)更新市场分析，包括市场规模、融资机制和可持续性；f)根据项目第一阶段的结果更新和扩展DRW的商业化战略；g)如果时间和资源允许，对SAMBA进行试验实施或培训。确定除大型政府方案之外的其他实施渠道将扩大SAMBA的使用，影响更多人的健康，并使DRW能够有益地利用SAMBA，从而支持测试需求，并为公司的工作和SAMBA产品创造可持续的未来。”

"DRW has developed SAMBA, a nucleic acid test system that can be used at the point of care in rural, remote locations to test for HIV viral load for therapy monitoring and early HIV infection diagnosis in infants born from HIV+ mothers to allow for early treatment. SAMBA instrument and tests are CE-marked, allowing use in Europe and Africa. DRW needs to develop the market and is working with ministries of health in several African countries and a hospital in Ukraine to implement SAMBA. In Africa, challenges associated with governments are proving to be a slow and circuitous process. However, there are private organisations working on the ground and in need of appropriate tools to test for HIV in remote, decentralised settings. DRW is already working with Médecins Sans Frontières and this project proposes to identify and quantify additional opportunities in private health organisations, such as faith-based health providers and non-governmental organisations, while continuing to work with government organisations.An estimated 100,000 faith-based organisations (FBO) in Africa provide health care to the poor and vulnerable and may provide 20% of global HIV/AIDS work. In Uganda, FBOs provide \>25% of all health services and private non-for-profits (including FBOs) account for 41% of hospitals and 22% of lower level health facilities. These organisations are highly motivated to provide health care to people in critical need but who cannot afford it. DRW proposes to identify and engage with such organisations in African and Eastern European markets, which are currently inaccessible, and develop a business strategy for delivering SAMBA to those markets. The information gathered will be used to develop an appropriate and sustainable strategy for supplying tests to these organisations. The following information will be researched: a) identify countries, organisations and sites for subsequent implementation in 'Phase 2'; b) determine number of tests needed per year; c) determine price acceptability; d) understand test site environment, facilities and users; e) update market analysis including market size, funding mechanisms and sustainability f) update and expand DRW's commercialisation strategy based on project Phase 1 outcomes and g) if time and resources allow, perform trial implementation or training for SAMBA. Determining additional implementation channels in addition to large government programmes will expand the use of SAMBA, impacting more people's health and allowing DRW to exploit SAMBA beneficially, thereby supporting testing needs and creating a sustainable future for the company's work and the SAMBA product."